Global Biosimilars Market Size, Share, Opportunities, And Trends By Type (Monoclonal Antibodies, Recombinant Proteins, Hormones, Others), By Disease (Infectious Disease, Oncology And Immunology, Respiratory, Genetic Disorders, Others), And By Geography – Forecasts From 2025 To 2030

Biosimilars Market Size:

The Biosimilars Market will reach US$50.901 billion in 2030 from US$24.176 billion in 2025 at a CAGR of 16.06% during the forecast period.

Biosimilars Market Trends:

Biosimilars are defined as licensed and highly similar versions of biological drugs that have already been approved for use by regulatory bodies. The growth in the market may be attributed to the cost-effectiveness of the biosimilars when compared to reference biologics, coupled with the patent expiration of the many blockbuster biologic drugs. The estimated patent and exclusivity expiry of a few of the blockbuster biologics is given below. Due to the structural complexity of biosimilar drugs, multi-layered manufacturing, and risk of immunogenicity, separate regulatory pathways have been drafted to introduce them into the market.

Biosimilars Market Growth Factors:

Increasing investment by the companies for the development of biosimilars will also be the key factor driving the market. 

Biosimilars Market Geographical Outlook:

Geographically, Europe holds the largest market share due to the presence of well-known biopharmaceutical companies such as Stada, Sandoz, AstraZeneca, Merck, etc.  Also, the well-defined regulatory framework for the approval of biosimilars and a rising number of product approvals, coupled with well-developed healthcare infrastructure, has further provided a boost to the European biosimilar market. Similarly, North America will also show robust growth during the forecast period, owing to the increasing focus on product development coupled with the rising efforts from the manufacturers to tap the growth opportunities in the region.

Market intelligence is presented in the form of analysis, charts, and graphics to help clients gain a faster and more efficient understanding of the global biosimilar market.

The biosimilars market report provides an in-depth analysis of the industry landscape, delivering strategic and executive-level insights backed by data-driven forecasts and analysis. This regularly updated report equips decision-makers with actionable intelligence on current market trends, emerging opportunities, and competitive dynamics. Biosimilars are defined as biologic products that are similar to already licensed biologic drugs, with minor differences in inactive components. The report also investigates technological advancements, key government policies, regulations, and macroeconomic factors, offering a comprehensive view of the market.

Biosimilars Market Segmentations:

Biosimilars Market Segmentation by type:

The market is analyzed by type into the following:

• Monoclonal antibodies
• Recombinant Proteins
• Hormones
• Others

Biosimilars Market Segmentation by disease

The market is analyzed by disease into the following:

• Infectious Disease
• Oncology and Immunology
• Respiratory
• Genetic Disorders
• Others

Biosimilars Market Segmentation by regions:

The study also analyzed the biosimilars in the following regions, with country-level forecasts and analysis as below:

• North America (US, Canada, and Mexico)
• South America (Brazil, Argentina, and Others)
• Europe (Germany, UK, France, Spain, and Others
• Middle East and Africa (Saudi Arabia, UAE, and Others)
• Asia Pacific (China, Japan, India, South Korea, Thailand, Indonesia, and Others)

Biosimilars Market Competitive Landscape:

The biosimilars market features key players such as Samsung Bioepis, Stada Arzneimittel AG, Sandoz International GmbH (Novartis), Amgen Inc., Apotex Inc., BioCad, Dr. Reddy’s Laboratories Ltd., Biocon, Boehringer Ingelheim International GmbH, Pfizer, BioFactura, and AmerisourceBergen Corporation among others.

Biosimilars Market Report Coverage:

This report provides extensive coverage as explained in the points below:

• Market size, forecasts, and trends by different types, with historical revenue data and analysis focusing on key factors driving adoption, current challenges faced by key players, and major growth areas.
• Market size, forecasts, and trends by technology, with historical revenue data and analysis.
• Market size, forecasts, and trends by application, with historical revenue data and analysis across various segments.
• The biosimilars market involves biologic drugs that are highly similar to reference products in terms of safety, purity, and potency. These drugs offer cost-effective alternatives to innovative biologics, making them attractive for treating chronic conditions like cancer and autoimmune diseases.
• Market dynamics: The section details the market growth factors, restraints, and opportunities in the market. The segment also presents a complete market scenario with the help of Porter’s five forces model. 
• Competitive Intelligence: A thorough investigation of the competitive structure of the market presented through a proprietary vendor matrix model, market share analysis of key players, insights on strategies of key players, and recent major developments undertaken by the companies to gain a competitive edge. 
• Research methodology: The assumptions and sources that were considered to arrive at the final market estimates. Additionally, how our model is refined to ensure the most significant factors are taken into consideration with the proper hypothesis and bottom-up and top-down approaches enhance the reliability of forecasts further strengthening the trustworthiness of the numbers being presented. 

How this report is helpful to you and reasons for the purchase?

• The report provides a strategic outlook of the surface computing market to the decision-makers, analysts, and other stakeholders in an easy-to-read format for making informed decisions.
• The charts, tables, and figures make it easy for the executives to gain valuable insights while skimming the report. 
• Analyst support through calls and emails for timely clarification and incorporating additional requests. 
• Option of presentation or doc format with the estimates file to take care of diverse requirements. 
• 15% FREE customization with all our reports to help cater to additional requirements with significant cost savings. 
• Option of purchasing specific segments of the study, including opting for summary reports or just the estimates file. 

Biosimilars Market Scope:

 

Report Metric	Details
Biosimilars Market Size in 2025	US$24.176 billion
Biosimilars Market Size in 2030	US$50.901 billion
Growth Rate	CAGR of 16.06%
Study Period	2020 to 2030
Historical Data	2020 to 2023
Base Year	2024
Forecast Period	2025 – 2030
Forecast Unit (Value)	USD Billion
Segmentation	Systems Loading Dock Type Industry Vertical Geography
Geographical Segmentation	North America, South America, Europe, Middle East and Africa, Asia Pacific
List of Major Companies in the Biosimilars Market	Ancra Systems. B.V Beumer Group GEBHARDT Fördertechnik GmbH Haver & Boecker OHG VDL Systems B.V
Customization Scope	Free report customization with purchase

 

Our Best-Performing Industry Reports:

• Monoclonal Antibodies Market
• Biobetters Market
• Biologics Market

---

1. EXECUTIVE SUMMARY 

2. MARKET SNAPSHOT

2.1. Market Overview

2.2. Market Definition

2.3. Scope of the Study

2.4. Market Segmentation

3. BUSINESS LANDSCAPE 

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities 

3.4. Porter’s Five Forces Analysis

3.5. Industry Value Chain Analysis

3.6. Policies and Regulations 

3.7. Strategic Recommendations 

4. TECHNOLOGICAL OUTLOOK

4.1. Product Pipeline

4.2. Patent Analysis

5. BIOSIMILARS MARKET BY TYPE

5.1. Introduction

5.2. Monoclonal antibodies

5.3. Recombinant Proteins

5.4. Hormones

5.5. Others

6. BIOSIMILARS MARKET BY DISEASE

6.1. Introduction

6.2. Infectious Disease

6.3. Oncology and Immunology

6.4. Respiratory

6.5. Genetic Disorders

6.6. Others

7. BIOSIMILARS MARKET BY GEOGRAPHY

7.1. Introduction

7.2. North America

7.2.1. USA

7.2.2. Canada

7.2.3. Mexico

7.3. South America

7.3.1. Brazil

7.3.2. Argentina

7.3.3. Others

7.4. Europe

7.4.1. United Kingdom

7.4.2. Germany

7.4.3. France

7.4.4. Italy

7.4.5. Spain

7.4.6. Others

7.5. Middle East and Africa

7.5.1. Saudi Arabia

7.5.2. UAE

7.5.3. Others

7.6. Asia Pacific

7.6.1. China

7.6.2. Japan

7.6.3. India

7.6.4. South Korea

7.6.5. Taiwan

7.6.6. Thailand

7.6.7. Indosneisa

7.6.8. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

8.1. Major Players and Strategy Analysis

8.2. Market Share Analysis

8.3. Mergers, Acquisitions, Agreements, and Collaborations

8.4. Competitive Dashboard

9. COMPANY PROFILES

9.1. Samsung Bioepis

9.2. Stada Arzneimittel AG

9.3. Sandoz International GmbH (Novartis)

9.4. Amgen Inc.

9.5. Apotex Inc.

9.6. BioCad

9.7. Dr. Reddy’s Laboratories Ltd.

9.8. Biocon

9.9. Boehringer Ingelheim International GmbH

9.10. Pfizer

9.11. BioFactura

9.12. AmerisourceBergen Corporation

10. APPENDIX

10.1. Currency 

10.2. Assumptions

10.3. Base and Forecast Years Timeline

10.4. Key benefits for the stakeholders

10.5. Research Methodology 

10.6. Abbreviations 

LIST OF FIGURES

LIST OF TABLES

Samsung Bioepis 

Stada Arzneimittel AG 

Sandoz International GmbH (Novartis) 

Amgen Inc. 

Apotex Inc. 

BioCad 

Dr. Reddy’s Laboratories Ltd. 

Biocon 

Boehringer Ingelheim International GmbH 

Pfizer 

BioFactura 

AmerisourceBergen Corporation